1. Home
  2. PLBY vs BDSX Comparison

PLBY vs BDSX Comparison

Compare PLBY & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.22

Market Cap

151.0M

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$30.63

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
BDSX
Founded
1953
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Precision Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
153.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PLBY
BDSX
Price
$1.22
$30.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$3.00
$32.50
AVG Volume (30 Days)
741.2K
107.1K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$120,928,000.00
$88,499,000.00
Revenue This Year
$9.17
$25.26
Revenue Next Year
$7.10
$19.15
P/E Ratio
N/A
N/A
Revenue Growth
4.13
24.08
52 Week Low
$1.08
$0.35
52 Week High
$2.75
$30.00

Technical Indicators

Market Signals
Indicator
PLBY
BDSX
Relative Strength Index (RSI) 49.81 67.14
Support Level $1.22 $19.26
Resistance Level $1.30 N/A
Average True Range (ATR) 0.08 2.23
MACD 0.00 0.40
Stochastic Oscillator 14.77 85.17

Price Performance

Historical Comparison
PLBY
BDSX

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: